Turnstone charts $75M IPO for TIL cell therapies in drumroll of biotech IPOs this month
Turnstone Biologics plans to list on the Nasdaq in a $75 million raise shortly after a trio of biotechs — Apogee Therapeutics, Sagimet Biosciences and 60 Degrees Pharmaceuticals — went public following a stretch of inactivity for the beleaguered sector.
The solid tumor cell therapy biotech hopes to mark a turnaround after losing key deals with AbbVie in 2021 and Takeda in 2022 and enacting layoffs last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.